Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Tyra Biosciences Inc

TYRA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$25.29

▲ +1.08%

Market Cap $1.51B · Vol 127.11K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.51B

Small Cap

Div Yield

N/A

EPS Growth

-30.21%

YoY

RSI (14)

30.39

Momentum

Beta

0.70

vs Market

52W High

$40.30

37.25% below

52W Low

$9.96

153.92% above

Volume

127.11K

Avg 224.33K

P/B

5.45

Price-to-book

ROE

-39.83%

Return on equity

Free Float

97.09%

Public shares

Shariah Compliance8 STANDARDS

✗ Tyra Biosciences Inc (TYRA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TYRA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.60%

-23.08%

-30.73%

-9.65%

YTD

-3.80%

+136.36%

+63.16%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-119,947,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-39.83%
ROA · ROIC	-37.13% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.45
P/FCF	N/A
EPS Growth	-30.21%
Outstanding Shares	59.68M

Technical Indicators

50-Day SMA	$29.65
200-Day SMA	$29.50
RSI (14)	30.39
Beta	0.70
52-Week High	$40.30
52-Week Low	$9.96

Volume Today	127.11K
Avg Daily Volume (30D)	224.33K
Relative Volume	0.57x
Volatility (10D)	117.13
Volatility (30D)	76.82
Free Float	97.09%

Analyst Consensus

BUY

Current Price $25.29

Mean Target $50.82

52W Low$9.96 52W High$40.30

Current

Target

$9.96 $40.30

Current Analyst target

+100.94% upside potential · 15 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00RCQD9F9

ISINUS90240B1061

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).